Stockscreener 앱 받기
41.35
3.43%
1.37
시장 영업 전:
41.36
0.010
+0.02%
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - theglobeandmail.com
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView
Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus
Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com
Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com UK
Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan
Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Kodiak Sciences, Inc. Statistics – HAM:K27 - TradingView
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - Sahm
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com - Investing.com India
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak completes enrollment in first KSI-101 trial cohort - Investing.com
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance
Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday - MarketBeat
KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Janus Henderson Group PLC Raises Stake in Kodiak Sciences Inc. $KOD - MarketBeat
57,400 Shares in Kodiak Sciences Inc. $KOD Acquired by Swiss National Bank - MarketBeat
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Kodiak Sciences, Inc. Revenue Breakdown – BMV:KOD - TradingView
Kodiak Sciences Inc (KOD) Institutional Confidence - TradingKey
Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kodiak Sciences Inc Revenue Breakdown – BOATS:KOD - TradingView
Kodiak Sciences Inc (KOD) Cash Flow - TradingKey
Kodiak Sciences Inc (KOD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KOD|Kodiak Sciences Inc|Price:42.020|Chg%:+0.610 - TradingKey
Kodiak Sciences Inc (KOD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kodiak Sciences Inc (KOD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kodiak Sciences Inc (KOD) Income Statement - tradingkey.com
Kodiak Sciences, Inc. Revenue Breakdown – LS:A2N6P0 - TradingView
KOD Q1 2026 Earnings: EPS Beat amid Pre-Revenue StageRevenue Beat Analysis - dars.gov.et
Why Did KOD Stock Surge To A Four-Year High Today? - Stocktwits
KOD|Kodiak Sciences Inc|Price:45.370|Chg%:-0.030 - TradingKey
Form 4 Kodiak Sciences Inc For: 17 July By Investing.com - Investing.com South Africa
Kodiak Sciences CEO Victor Perlroth Awarded 100,000 Stock Options at $42.42 Exercise Price - Kalkine Media
Kodiak Sciences CFO John Borgeson Awarded 66,500 Stock Options with Four-Year Vesting - Kalkine Media
Kodiak Sciences Inc. (KOD) awards CFO 66,500 stock options - Stock Titan
Kodiak Sciences (KOD) awards CEO Perlroth 100,000 stock options - Stock Titan
Frontier tech research, news & data - MLQ.ai
Y Intercept Hong Kong Ltd Sells 27,959 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
0.52%
0.07%
자본화:
|
볼륨(24시간):